The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

Evaluating and managing lid margin disease and meibomian gland dysfunction.

Catch up on what happened in optometry during the week of April 15-April 19.

The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.

Creating an accessible office allows those most in need to receive care.

Andrew S. Morgenstern, OD, FAAO, FNAP, joins Dr. Korik to discuss a newly published study on the incidence of keratoconus among pediatric patients in a Chicago-based study. The pair also discuss the International Keratoconus Academy, and Morgenstern's experience working at Walter Reed Medical Center.

The new service, PolicyWatch, allows optometric practices and service providers as well as telemedicine solution companies to access real-time policy changes in their area of practice, spanning all 50 states and the District of Columbia.

UPFs include fast food, energy drinks and soda, sweets such as chocolates and candies, and much more.

Control measures in China are ahead of US measures.

Results from the THRIVE study found that when reading glasses were given to first-time wearers, monthly median incomes increased by 33%.

Trial findings show efficacy of lotilaner for killing mites

Catch up on what happened in optometry during the week of April 8-April 12.

Pterygium is an ocular disease commonly referred to as “surfer’s eye,” which can result from exposure to high levels of UV radiation.

Before the ASCRS 2024 meeting, TheiaNova CEO Carissa Fonseca, PhD, pitched a novel keratoconus treatment.